eNAMPT Is a Novel DAMP and Therapeutic Target in Human and Murine Pulmonary Fibrosis

Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal disorder without curative therapies, underscoring the critical unmet need for identification of novel therapeutic strategies. eNAMPT (extracellular nicotinamide phosphoribosyltransferase) is a damage-associated molecular pattern protein (DAMP) and TLR4 (Toll-like receptor 4) ligand that contributes to the severity of radiation-induced lung fibrosis and nonalcoholic steatohepatitis-associated hepatic fibrosis. This study investigates eNAMPT as a druggable target in human and preclinical IPF using the eNAMPT-neutralizing ALT-100 monoclonal antibody (mAb). Blood, peripheral blood mononuclear cells (PBMCs), and lung tissues from patients with IPF and from an experimental bleomycin-induced lung fibrosis model in C57Bl6 mice were analyzed. Biochemical and histologic measurements, as well as gene expression through bulk and single-cell RNA sequencing of human PBMCs and murine lung tissues, were performed. Human studies revealed NAMPT expression to be significantly increased in plasma, lung tissues, and PBMCs from subjects with IPF, correlating with disease severity and inversely associated with IPF survival. Bleomycin-exposed mice exhibited increased inflammatory indices associated with lung fibrosis development (including NAMPT levels), as well as physiologic lung stiffening and TGF-β pathway-related protein and gene expression, with each index significantly mitigated in mice receiving ALT-100 mAb. Single-cell RNA sequencing studies demonstrated the ALT-100 mAb to reverse the bleomycin-induced dramatic expansion of alveolar type 2 epithelium and induction of endothelial cell- and epithelial cell-to-mesenchymal/myofibroblast transitions. These finding support the fundamental involvement of eNAMPT/TLR4 signaling pathway in lung fibrosis pathobiology, with eNAMPT neutralization a viable therapeutic strategy to directly address the unmet need for novel IPF treatments.

Authors

Institutions

Publication Details

Journal
American Journal of Respiratory Cell and Molecular Biology
Published
2025-03-24
DOI
https://doi.org/10.1165/rcmb.2024-0342oc
Citations
9
Primary Topic
Inhalation and Respiratory Drug Delivery
Type
article
Field-Weighted Citation Impact
13.67
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

eNAMPT Is a Novel DAMP and Therapeutic Target in Human and Murine Pulmonary Fibrosis

Nancy G. Casanova, Carrie L. Kempf, Donna D. Zhang, Theodoros Karampitsakos et al.
9 citations
American Journal of Respiratory Cell and Molecular Biology
Inhalation and Respiratory Drug Delivery
13.67
article

eNAMPT Is a Novel DAMP and Therapeutic Target in Human and Murine Pulmonary Fibrosis

Nancy G. Casanova, Carrie L. Kempf, Donna D. Zhang, Theodoros Karampitsakos, Jose D. Herazo‐Maya, Matthew K. Hufford, Matthew D. Disney, Ben N. Stansfield, Riley D. Hellinger, Iván O. Rosas, Panayiotis V. Benos, Christian Bime, Jin H. Song, Sara M. Camp, Joe G. N. Garcia, Julie G. Ledford, Shaira Limson Kee, Nahla Zaghloul, Belinda Sun, Victor J. Thannickal, Jinjing Chen, Avraham Unterman, Saad Sammani, Naftali Kaminski, Annadurai Anandhan, Akash Gupta, Amy Zhao, Mohamed Ahmed, Aikseng Ooi, Steve Duncan, Marisela Rodriguez, Annie Hernandez, Jason Canizales Galaviz
article en
9 citations

Abstract

Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal disorder without curative therapies, underscoring the critical unmet need for identification of novel therapeutic strategies. eNAMPT (extracellular nicotinamide phosphoribosyltransferase) is a damage-associated molecular pattern protein (DAMP) and TLR4 (Toll-like receptor 4) ligand that contributes to the severity of radiation-induced lung fibrosis and nonalcoholic steatohepatitis-associated hepatic fibrosis. This study investigates eNAMPT as a druggable target in human and preclinical IPF using the eNAMPT-neutralizing ALT-100 monoclonal antibody (mAb). Blood, peripheral blood mononuclear cells (PBMCs), and lung tissues from patients with IPF and from an experimental bleomycin-induced lung fibrosis model in C57Bl6 mice were analyzed. Biochemical and histologic measurements, as well as gene expression through bulk and single-cell RNA sequencing of human PBMCs and murine lung tissues, were performed. Human studies revealed NAMPT expression to be significantly increased in plasma, lung tissues, and PBMCs from subjects with IPF, correlating with disease severity and inversely associated with IPF survival. Bleomycin-exposed mice exhibited increased inflammatory indices associated with lung fibrosis development (including NAMPT levels), as well as physiologic lung stiffening and TGF-β pathway-related protein and gene expression, with each index significantly mitigated in mice receiving ALT-100 mAb. Single-cell RNA sequencing studies demonstrated the ALT-100 mAb to reverse the bleomycin-induced dramatic expansion of alveolar type 2 epithelium and induction of endothelial cell- and epithelial cell-to-mesenchymal/myofibroblast transitions. These finding support the fundamental involvement of eNAMPT/TLR4 signaling pathway in lung fibrosis pathobiology, with eNAMPT neutralization a viable therapeutic strategy to directly address the unmet need for novel IPF treatments.

American Journal of Respiratory Cell and Molecular BiologyVol. 73(4)
Tulane University (US), Scripps Research Institute (US), Brigham and Women's Hospital (US), University of Arizona (US), Baylor University (US), University of Pittsburgh (US), Baylor College of Medicine (US), University of South Florida (US), Tel Aviv Sourasky Medical Center (IL), University of Alabama at Birmingham (US), Yale University (US), University of Florida (US), Baylor School (US), Institute for Learning Innovation (US), Banner - University Medical Center Tucson (US), Inflammation Research Foundation (US), Jupiter (United States) (US), Cellular Research (United States) (US), Centre for Inflammation Research (GB), The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology, University of Tampa (US), Florida College (US)
Openalex Percentile: Top 1%
Inhalation and Respiratory Drug Delivery
13.67
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.